Body composition is minimally investigated in an immunotherapy era. Specific body composition signals such as myosteatosis may reflect aspects of patients' immunology and thereby their ability to respond to immunotherapies. Ipilimumab is a key checkpoint inhibitor in metastatic melanoma. As an antibody, it may also be more accurately dosed using body composition parameters rather than weight alone. This retrospective study aimed to investigate body composition‐based dosing and outcomes.

中文翻译：

---

身体成分是转移性黑色素瘤中易普利姆玛活性的预后和预测因素。

在免疫治疗时代，对身体成分的研究最少。特定的身体成分信号（如肌肉脂肪变性）可能反映患者免疫学的各个方面，从而反映他们对免疫疗法的反应能力。Ipilimumab 是转移性黑色素瘤的关键检查点抑制剂。作为一种抗体，它也可以使用身体成分参数而不是单独的体重来更准确地给药。这项回顾性研究旨在调查基于身体成分的剂量和结果。